Research ArticleResearchWorkflowMedication Safety

Chemotherapy-first rectal-cancer regimen improved pathologic response in a randomized trial

Journal of Gastrointestinal Cancer (PubMed)Jul 25, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A randomized trial of 202 people with locally advanced rectal cancer found a higher pathologic complete response rate when chemotherapy preceded chemoradiotherapy and surgery than when chemoradiotherapy came first, while overall-survival results remained immature.

What NurseJet pulled from the source

Participants were assigned to chemotherapy-first total neoadjuvant therapy or conventional chemoradiotherapy followed by adjuvant chemotherapy and surgery. Pathologic complete response occurred in 55.4% versus 42.57%, respectively. Surgical outcomes were similar; thrombocytopenia was less frequent and dysuria more frequent with chemotherapy-first treatment. Overall survival did not differ significantly at the available follow-up.

Why this matters for nurses

Oncology nurses coordinate multi-stage treatment, monitor cumulative toxicity, reinforce symptom reporting, and help patients navigate transitions between chemotherapy, radiation, and surgery. A change in sequence shifts when those assessments, education needs, and handoffs occur even when the treatment components remain familiar.

Bedside takeaway

Chemotherapy-first treatment improved pathologic response, but the trial did not establish a survival advantage.

How This Applies in Practice

Use this when: Coordinating care for a patient receiving a multi-stage neoadjuvant regimen for locally advanced rectal cancer.

On your shift

Verify the treatment phase, next transition, and current monitoring plan during every oncology handoff.
Trend and escalate regimen-specific hematologic, urinary, gastrointestinal, and functional concerns through the oncology pathway.
When reinforcing education, distinguish the study's pathologic-response result from its still-immature survival evidence.

Keep in mind: This trial does not independently determine treatment selection or sequencing for an individual patient. Follow the oncology protocol, facility policy, and patient-specific provider orders.

Key takeaways

The trial randomized 202 participants, with 101 assigned to each treatment sequence.
Pathologic complete response was 55.4% with chemotherapy-first treatment and 42.57% with the conventional sequence.
Sphincter preservation, resection margins, and surgical complications were similar between groups.
The survival analysis was exploratory and immature, so the response difference does not establish a long-term survival benefit.

Practice implications

Confirm the current phase and sequence at each handoff, reconcile treatment-specific monitoring and supportive-care plans, and promptly communicate hematologic, urinary, gastrointestinal, or other concerning symptoms. Present pathologic response and survival as separate outcomes during education.

Limitations & cautions

The trial addressed a resource-limited context and enrolled 202 participants. Overall survival was a secondary exploratory outcome and follow-up was not mature; larger studies with longer follow-up are needed before inferring a survival advantage or broad generalizability.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Journal of Gastrointestinal Cancer (PubMed)

Journal of Gastrointestinal Cancer (PubMed). Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42501213/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Supportive care in cancer (PubMed)Sep 5, 2026Research Article

A small randomized trial found larger one-month reductions in reported supportive-care needs among colorectal cancer caregivers who received smartphone-based education than with routine care.

OncologyAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Eighty family caregivers at two teaching hospitals in Tehran were randomized. Compared with routine care, the intervention group reported larger reductions in total needs and in health-service, psychological-emotional, work-social, and information domains after four weeks.

Key takeaways

The intervention was designed around family caregivers' supportive-care needs.
All four measured need domains favored the smartphone-education group at four weeks.
The abstract reports statistical significance but does not provide effect sizes or describe the educational content in detail.

Why this matters on shift

Caregiver education is part of oncology care, and mobile delivery may extend structured support beyond brief in-person teaching encounters.

Bedside takeaway

Ask caregivers about unmet information and support needs, then reinforce teaching with approved digital resources.

Nursing implications

Assess what caregivers still need to know and use approved digital education as a supplement to individualized teaching and follow-up.

Limitations & cautions

Abstract-only summary. The trial included 80 caregivers at two hospitals, assessed self-reported needs after only four weeks, and did not report patient outcomes or effect sizes in the abstract.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Supportive care in cancer (PubMed). The effect of a smartphone-based educational intervention on the supportive care needs of family caregivers of patients with colorectal cancer: a randomized controlled trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

The New England journal of medicine (PubMed)Sep 3, 2026Research ArticlePractice applicable

A phase 2 randomized trial favored azacitidine-venetoclax over induction chemotherapy for event-free survival in selected adults with untreated AML.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPractice applicableAI summary · original source linked below

Among 172 participants, median event-free survival was 14.5 versus 6.2 months (hazard ratio for event or death 0.57; 95% CI 0.39-0.84). Median follow-up was 21.9 months.

Key takeaways

Grade 3 or higher infection occurred in 28% versus 41%, respectively.
Grade 3 or higher hemorrhage occurred in 2% versus 12%, respectively.

Why this matters on shift

The result informs treatment discussions, while serious infection and bleeding remain relevant nursing concerns.

Bedside takeaway

Avoid generalizing this phase 2 result to every patient with AML.

Nursing implications

Reinforce the individualized oncology plan and communicate infection or bleeding concerns promptly.

Limitations & cautions

Abstract-only summary of an industry-funded phase 2 trial. Core-binding-factor fusions, FLT3 mutations, and NPM1 mutations in patients under 60 were excluded. Event-free survival is not overall survival.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

The New England journal of medicine (PubMed). Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

The American journal of managed care (PubMed)Aug 1, 2026Research ArticlePractice applicable

A post hoc randomized-trial analysis found lower symptom-management self-efficacy identified breast cancer survivors with poorer outcomes who appeared to benefit most from remote monitoring plus tailored messages.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchPatient EducationWorkflowPractice applicableAI summary · original source linked below

The analysis included 264 women prescribed adjuvant endocrine therapy and compared enhanced usual care, weekly app monitoring, and app monitoring plus tailored supportive texts. Higher baseline self-efficacy was associated with lower symptom burden and greater adherence. At a low self-efficacy score of 30, estimated adherence was 52.7% with app plus feedback versus 17.8% with usual care, but the confidence interval was wide and the subgroup analysis was post hoc.

Key takeaways

The post hoc analysis included 264 women from a randomized trial of app-based symptom and adherence monitoring.
Higher baseline symptom-management self-efficacy was associated with lower symptom burden and greater odds of endocrine-therapy adherence.
The tailored-feedback intervention showed its largest estimated adherence benefit at lower self-efficacy levels.
The low-self-efficacy estimate had a wide confidence interval, and effects diminished and became nonsignificant at higher self-efficacy levels.

Why this matters on shift

Endocrine-therapy symptoms and low confidence managing them can undermine long-term treatment. Oncology nurses can identify support needs, normalize symptom reporting, and close the loop with the oncology team while recognizing that an app is an adjunct rather than a replacement for care.

Bedside takeaway

Low confidence managing endocrine-therapy symptoms can be a cue for more tailored follow-up and adherence support.

Nursing implications

Ask how confident the patient feels managing symptoms and the daily regimen, then assess barriers, symptom burden, missed doses, and support preferences. Route concerns through the survivorship or oncology pathway and use remote monitoring only within the approved program.

Limitations & cautions

This was a post hoc effect-modification analysis rather than a prespecified primary comparison. Adherence was recorded with a connected pillbox, the low-self-efficacy estimate was imprecise, and the findings do not establish that the same intervention will work in other populations or platforms.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

The American journal of managed care (PubMed). Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Smartphone education reduced reported support needs among colorectal cancer caregivers

Azacitidine-venetoclax prolonged event-free survival in a selected induction-eligible AML population

Tailored remote support may help breast cancer survivors with low self-efficacy